治疗性放射性药物外渗:系统综述与管理建议
该系统综述检索MEDLINE和Embase,纳入28篇文献共39例外渗病例报告,汇总治疗性放射性药物外渗的后果与处理方式。外渗严重程度取决于渗漏活度、滞留时间和粒子辐射能量;放射性滑膜切除术或大分子药物外渗可致严重辐射损伤,而PRRT或PSMA靶向治疗外渗未见辐射损伤报告。作者据此提出标准化分步管理建议。
要点
- 外渗严重程度由渗漏活度、滞留时间和粒子辐射能量决定。
- 最常见急性反应为暂时性肿胀、疼痛和发红。
- 最常见干预为活动患肢,包括按摩、抬臂、握力球或手部泵动练习。
核心结论
- 治疗性放射性药物外渗是罕见报告的并发症,其严重程度由渗漏活度、滞留时间和粒子辐射能量决定。
- 放射性滑膜切除术或大分子药物(如[90Y]Y-ibritumomab tiuxetan)外渗后可见严重辐射损伤。
- 截至文献汇总时,肽受体放射性核素治疗或PSMA靶向放射性药物治疗外渗后未见辐射损伤病例报告。
研究设计与样本
- 系统综述,检索MEDLINE和Embase数据库,检索词分别涵盖外渗同义词和治疗性放射性药物名称。
- 纳入治疗性放射性药物外渗的病例报告,对命名和吸收剂量单位进行标准化。
- 筛选3033篇摘要、全文审查75篇出版物,并筛查纳入文献及EANM治疗性放射性药物指南的参考文献,最终纳入28篇出版物共39例外渗病例报告。
主要发现
- 副作用严重程度差异大,从轻微且快速消退到严重不等,取决于所用放射性药物。
- 最常见的急性副作用为暂时性肿胀、疼痛和发红。
- 辐射损伤程度从红斑、干性或湿性脱屑到坏死,与吸收剂量相关。
- 最常报告的干预为活动患肢,包括按摩、抬臂、握力球使用或手部泵动练习。
- 预防外渗的管理策略主要集中于确保充分的血管通路。
关键数值与推荐
- 报告的吸收剂量、副作用和处理方法按放射性药物分组汇总。
- 提出的管理策略按作者时间顺序总结。
临床怎么用
- 外渗后应活动患肢,可采用按摩、抬臂、握力球或手部泵动练习。
- 预防外渗应重点确保充分的血管通路。
- 对放射性滑膜切除术或大分子药物治疗外渗需警惕严重辐射损伤。
局限性
- 外渗为罕见报告的并发症,证据基于39例病例报告。
- 原文未报告病例报告的具体随访时长及报告偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The extravasation of therapeutic radiopharmaceuticals presents a risk of radiation-induced injury. The recent rise in the use of therapeutic radiopharmaceuticals has highlighted the need for a better understanding of the consequences of extravasation and different treatment approaches, which are summarized in this systematic review. Here, we propose a standardized, step-by-step management guide with the aim of integrating this approach into future guidelines. Methods: A search of MEDLINE and Embase databases was conducted. The first search string contained synonyms of extravasation The second search string contained the names of therapeutic radiopharmaceuticals. Case reports on extravasation of therapeutic radiopharmaceuticals were included in the analysis. Extracted data were standardized for nomenclature and absorbed dose units. Reported absorbed doses, side effects, and treatment approaches were grouped by radiopharmaceutical. Proposed management strategies were summarized chronologically by author. Results: After screening 3,033 abstracts, conducting a full-text review of 75 publications, and screening all references of included publications and European Association of Nuclear Medicine guidelines on therapeutic radiopharmaceuticals, 28 publications remained, involving 39 case reports of extravasation of therapeutic radiopharmaceuticals. The severity of side effects varied widely, from mild and quickly resolving to severe, depending on the radiopharmaceutical used. The most frequent acute side effects were transient swelling, pain, and redness. In cases of radiation injury, the degree of severity, ranging from erythema and dry or moist desquamation to necrosis, was related to the absorbed dose. The most frequently reported intervention after extravasation was mobilization of the affected limb, which included massage, elevation of the arm, stress ball use, or hand-pumping exercises. Management strategies to prevent extravasation focused mainly on ensuring adequate vascular access. Conclusion: Extravasation of therapeutic radiopharmaceuticals is a rarely reported complication, with its severity determined by the activity infiltrated, retention time, and energy of the particulate radiation. Severe radiation-induced injuries were observed after radiosynoviorthesis or extravasation of large molecules (e.g., [90Y]Y-ibritumomab tiuxetan). To date, there have been no reported cases of radiation-induced damage after extravasation during peptide receptor radionuclide therapy or prostate-specific membrane antigen-targeted radiopharmaceutical therapy. This systematic review highlights the consequences of 39 documented cases of extravasation of therapeutic radiopharmaceuticals and offers a step-by-step management guide.
引用
- Gebruers J, Terwinghe C, Graven LH, et al. Extravasation of Therapeutic Radiopharmaceuticals: A Systematic Review and Management Proposal. J Nucl Med. 2025. PMID: 41130791. doi:10.2967/jnumed.125.270215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。